Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2024-12-19 Sale | 2024-12-20 8:33 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 51,115 | $0.94 | $48,048 | 326,904 (Direct) | View |
2024-12-17 Sale | 2024-12-19 9:08 pm | NEKTAR THERAPEUTICS | NKTR | ROBIN HOWARD W President & CEO | 132,030 | $0.99712 | $131,650 | 1,111,085 (Indirect Direct) | View |
2024-11-19 Sale | 2024-11-20 8:37 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 7,785 | $1.01 | $7,863 | 243,019 (Direct) | View |
2024-11-19 Sale | 2024-11-20 8:36 pm | NEKTAR THERAPEUTICS | NKTR | Wilson Mark Andrew Chief Legal Officer | 6,407 | $1.01 | $6,471 | 218,856 (Direct) | View |
2024-11-19 Sale | 2024-11-20 8:36 pm | NEKTAR THERAPEUTICS | NKTR | ROBIN HOWARD W President & CEO | 16,278 | $1.01 | $16,441 | 832,490 (Indirect Direct) | View |
2024-08-19 Sale | 2024-08-20 9:15 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 6,866 | $1.28 | $8,788 | 250,804 (Direct) | View |
2024-08-19 Sale | 2024-08-20 9:15 pm | NEKTAR THERAPEUTICS | NKTR | Wilson Mark Andrew Chief Legal Officer | 5,651 | $1.28 | $7,233 | 225,263 (Direct) | View |
2024-08-19 Sale | 2024-08-20 9:14 pm | NEKTAR THERAPEUTICS | NKTR | ROBIN HOWARD W President & CEO | 14,881 | $1.28 | $19,048 | 848,768 (Indirect Direct) | View |
2024-06-14 Sale | 2024-06-14 6:02 pm | NEKTAR THERAPEUTICS | NKTR | CHESS ROBERT Director | 19,500 | $1.2 | $23,400 | 261,573 (Indirect Direct) | View |
2024-05-17 Sale | 2024-05-20 9:14 pm | NEKTAR THERAPEUTICS | NKTR | ROBIN HOWARD W President & CEO | 16,650 | $1.75 | $29,138 | 863,649 (Indirect Direct) | View |
2024-05-17 Sale | 2024-05-20 9:13 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 7,355 | $1.75 | $12,871 | 257,670 (Direct) | View |
2024-05-17 Sale | 2024-05-20 9:12 pm | NEKTAR THERAPEUTICS | NKTR | Wilson Mark Andrew Chief Legal Officer | 6,260 | $1.75 | $10,955 | 230,414 (Direct) | View |
2024-05-10 Sale | 2024-05-13 4:36 pm | NEKTAR THERAPEUTICS | NKTR | Deep Track Capital LP Deep Track Biotechnology Master Fund Ltd. KROIN DAVID 10% Owner | 56,000 | $1.7791 | $99,630 | 18,344,000 (Indirect) | View |
2024-02-20 Sale | 2024-02-22 8:19 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 9,014 | $0.68 | $6,130 | 265,025 (Direct) | View |
2024-02-20 Sale | 2024-02-22 8:17 pm | NEKTAR THERAPEUTICS | NKTR | Wilson Mark Andrew Chief Legal Officer | 7,606 | $0.68 | $5,172 | 236,674 (Direct) | View |
2024-02-20 Sale | 2024-02-22 8:16 pm | NEKTAR THERAPEUTICS | NKTR | ROBIN HOWARD W President & CEO | 20,033 | $0.68 | $13,622 | 880,299 (Indirect Direct) | View |
2023-11-17 Sale | 2023-11-20 9:02 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 9,646 | $0.49 | $4,727 | 274,039 (Direct) | View |
2023-11-17 Sale | 2023-11-20 9:00 pm | NEKTAR THERAPEUTICS | NKTR | Wilson Mark Andrew Chief Legal Officer | 7,179 | $0.49 | $3,518 | 243,780 (Direct) | View |
2023-11-17 Sale | 2023-11-20 8:58 pm | NEKTAR THERAPEUTICS | NKTR | ROBIN HOWARD W President & CEO | 19,877 | $0.49 | $9,740 | 900,332 (Indirect Direct) | View |
2023-09-18 Sale | 2023-09-20 8:09 pm | NEKTAR THERAPEUTICS | NKTR | Curet Myriam Director | 4,359 | $0.69 | $3,008 | 112,418 (Direct) | View |
2022-09-22 Sale | 2023-09-20 8:08 pm | NEKTAR THERAPEUTICS | NKTR | CHESS ROBERT Director | 10,200 | $0.67 | $6,834 | 366,073 (Indirect Direct) | View |
2023-09-18 Sale | 2023-09-20 8:06 pm | NEKTAR THERAPEUTICS | NKTR | Ajer Jeffrey Robert Director | 4,359 | $0.69 | $3,008 | 119,153 (Direct) | View |
2023-08-16 Sale | 2023-08-17 8:08 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 9,703 | $0.78 | $7,568 | 283,685 (Direct) | View |
2023-08-16 Sale | 2023-08-17 8:07 pm | NEKTAR THERAPEUTICS | NKTR | Wilson Mark Andrew Chief Legal Officer | 7,221 | $0.78 | $5,632 | 250,959 (Direct) | View |
2023-08-16 Sale | 2023-08-17 8:06 pm | NEKTAR THERAPEUTICS | NKTR | ROBIN HOWARD W President & CEO | 19,998 | $0.78 | $15,598 | 920,209 (Indirect Direct) | View |
2023-06-14 Sale | 2023-06-15 6:26 pm | NEKTAR THERAPEUTICS | NKTR | WHITFIELD ROY A Director | 30,000 | $0.57 | $17,100 | 287,750 (Indirect Direct) | View |
2023-05-16 Sale | 2023-05-17 8:29 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 9,791 | $0.72 | $7,050 | 293,388 (Direct) | View |
2023-05-16 Sale | 2023-05-17 8:28 pm | NEKTAR THERAPEUTICS | NKTR | Wilson Mark Andrew Chief Legal Officer | 7,543 | $0.72 | $5,431 | 257,680 (Direct) | View |
2023-05-16 Sale | 2023-05-17 8:27 pm | NEKTAR THERAPEUTICS | NKTR | ROBIN HOWARD W President & CEO | 20,361 | $0.72 | $14,660 | 940,207 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2024-12-13 Option Award | 2024-12-17 8:55 pm | N/A 2030-08-14 | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 780,000 | $0 | 1,023,019 (Direct) | View |
2024-12-13 Option Award | 2024-12-17 8:54 pm | N/A 2030-08-14 | NEKTAR THERAPEUTICS | NKTR | Wilson Mark Andrew Chief Legal Officer | 822,813 | $0 | 1,042,169 (Direct) | View |
2024-12-13 Option Award | 2024-12-17 8:54 pm | N/A 2030-08-14 | NEKTAR THERAPEUTICS | NKTR | ROBIN HOWARD W President & CEO | 2,531,875 | $0 | 3,364,365 (Direct) | View |
Ownership | 2024-03-14 4:30 pm | N/A N/A | NEKTAR THERAPEUTICS | NKTR | Deep Track Capital LP Deep Track Biotechnology Master Fund Ltd. KROIN DAVID 10% Owner | 0 | $0 | 18,400,000 (Indirect) | View |
2023-12-13 Option Award | 2023-12-15 6:07 pm | N/A 2031-12-12 | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 250,000 | $0 | 250,000 (Direct) | View |
2023-12-13 Option Award | 2023-12-15 6:05 pm | N/A 2031-12-12 | NEKTAR THERAPEUTICS | NKTR | Wilson Mark Andrew Chief Legal Officer | 325,000 | $0 | 325,000 (Direct) | View |
2023-12-13 Option Award | 2023-12-15 6:05 pm | N/A 2031-12-12 | NEKTAR THERAPEUTICS | NKTR | ROBIN HOWARD W President & CEO | 1,300,000 | $0 | 1,300,000 (Direct) | View |
2023-09-19 Option Award | 2023-09-21 8:07 pm | N/A 2031-09-18 | NEKTAR THERAPEUTICS | NKTR | GREER R SCOTT Director | 85,000 | $0 | 85,000 (Direct) | View |
2023-09-19 Option Award | 2023-09-20 8:11 pm | N/A 2031-09-18 | NEKTAR THERAPEUTICS | NKTR | WHITFIELD ROY A Director | 85,000 | $0 | 85,000 (Direct) | View |
2023-09-19 Option Award | 2023-09-20 8:09 pm | N/A 2031-09-18 | NEKTAR THERAPEUTICS | NKTR | Curet Myriam Director | 85,000 | $0 | 112,418 (Direct) | View |
2023-09-19 Option Award | 2023-09-20 8:08 pm | N/A 2031-09-18 | NEKTAR THERAPEUTICS | NKTR | CHESS ROBERT Director | 85,000 | $0 | 366,073 (Direct) | View |
2023-09-19 Option Award | 2023-09-20 8:07 pm | N/A 2031-09-18 | NEKTAR THERAPEUTICS | NKTR | Brainard Diana Director | 85,000 | $0 | 85,000 (Direct) | View |
2023-09-19 Option Award | 2023-09-20 8:06 pm | N/A 2031-09-18 | NEKTAR THERAPEUTICS | NKTR | Ajer Jeffrey Robert Director | 85,000 | $0 | 119,153 (Direct) | View |